Posts

GSK strikes up to $750 million deal for Chimagen blood-cancer therapy

on

ArsenalBio cuts 99 jobs in pivot to in vivo CAR-T

on

FDA approves first-in-class Mimrylo for rare blood cancer

on

Zealand Sells Rights to Takeda’s Blood Cancer Drug for $100M Ahead of FDA Approval Decision

on

Gene‑silencing drug divesiran posts strong Phase 2 win in rare blood cancer

on

Roche Launches Up to $2.3B Blood‑Cancer Bet Around Nurix’s BTK Degrader Bexobrutideg

on

FDA Extends Orca Bio Orca-T Review Timeline Following Manufacturing Data Submission

on

Ipsen Withdraws Tazverik from Market Due to Secondary Malignancy Safety Concerns

on

Orca Bio Presents Clinical Data on High-Precision Cell Therapies at 52nd EBMT Annual Meeting

on

Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

on

FDA restricts bluebird bio’s Skysona to CALD patients without suitable stem cell donors after higher blood cancer risk emerges

on

FDA tightens Skysona label, restricting use to CALD patients without alternative options due to increased blood cancer risk

on

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

on